E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 12.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10067584 |
E.1.2 | Term | Type 1 diabetes mellitus |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
1. Day 6 of 6 days (6D) of pump reservoir in-use of Humalog is noninferior to Day 6 of 6D of pump reservoir in-use of insulin aspart with regards to 7-point daily mean SMBG (with a margin of 0.6 mmol/L) 2. Day 6 of 6D of pump reservoir in-use of Humalog is superior to Day 6 of 6D of pump reservoir in-use of insulin apart with regards to 7-point daily mean SMBG
|
|
E.2.2 | Secondary objectives of the trial |
● Day 6 of 6D Humalog is noninferior to Day 2 of 6D Humalog with regards to mean SMBG (margin = 0.6 mmol/L) ● Compare 6D Humalog to 6D insulin aspart with respect to mean SMBG, insulin dose, hypoglycemic events, pump complications, hyperglycemic events, adverse events (AEs), and HbA1c ● Compare Days 1 through 6 of 6D Humalog to Days 1 through 6 of 6D insulin aspart individually and cumulatively with respect to mean SMBG, insulin dose, hypoglycemic events, pump complications, and hyperglycemic events ● Compare Days 1 through 3 with Days 4 through 6 individually and cumulatively of 6D Humalog and 6D insulin aspart, between and within treatment groups with respect to mean SMBG, insulin dose, hypoglycemic events, pump complications, and hyperglycemic events ● Compare Days 1 and 2 with Days 4 and 5 of 6D Humalog and 6D insulin aspart between and within treatment groups with respect to mean SMBG, insulin dose, hypoglycemic events, pump complications, and hyperglycemic events
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1] Diagnosed with type 1 diabetes (World Health Organization [WHO] criteria) for at least 24 months. [2] Age >= 13 years. [3] Treated with CSII therapy for the previous 6 months. [4] Mean total daily insulin dose for 3 days prior to screening <=46 units (U)/day using a 300-U reservoir or <=26 U/day using a 180–U reservoir. [5] Baseline body mass index (BMI) <=35.0 kg/m2. [6] Baseline HbA1c 5% to 9%.
|
|
E.4 | Principal exclusion criteria |
7] Currently using continuous glucose monitoring (CGM), unless patients agree to not use their personal CGM during the study. [8] Impaired renal function (serum creatinine >=2.0 mg/dL). [9] Legal blindness. [10] Have had any episode in previous 12 months prior to Visit 1 of hypoglycemic coma, seizures, or disorientation. [11] Have had hypoglycemia unawareness (routinely asymptomatic at BG <45 mg/dL) in the 12 months prior to Visit 1. [12] Have had any emergency room visits or hospitalizations due to poor glucose control in the 12 months prior to Visit 1. [13] Have had a pump-related infusion site abscess in the 12 months prior to Visit 1. [14] Have had multiple, clinically significant occlusions as judged by the investigator. [15] Have had any infection with Staphylococcus aureus in the past 5 years. [16] Have one of the following concomitant diseases: presence of clinically significant hematologic, oncologic, renal, cardiac, hepatic, or gastrointestinal disease, or any other serious disease considered by the investigator to be exclusionary. [17] Patients with malignancy other than basal cell or squamous cell skin cancer who have not yet been treated, are currently being treated, or who were diagnosed less than 5 years ago. [18] Have had a blood transfusion or severe blood loss within previous 3 months prior to Visit 1 or have known hemoglobinopathy, hemolytic or sickle cell anemia, or any other traits of hemoglobin abnormalities known to interfere with HbA1c methodology. [19] Are receiving chronic (lasting longer than 14 consecutive days) systemic glucocorticoid therapy (excluding topical, intra-articular, intra-ocular, and inhaled prescriptions), or have received such therapy within the 4 weeks immediately preceding Visit 1. [20] Have an irregular sleep/wake cycle (for example, patients who sleep during the day and work during the night) in the investigator’s opinion. [21] Have known hypersensitivity or allergy to any of the study insulins or their excipients. [22] Are breastfeeding or pregnant, or intend to become pregnant during the course of the study, or are sexually active women of childbearing potential not actively practicing birth control by a method determined by the investigator to be medically acceptable. [23] Are investigator site personnel directly affiliated with this study and/or their immediate families. Immediate family is defined as a spouse, parent, child, or sibling, whether biological or legally adopted. [24] Are Lilly employees. [25] Are currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an off-label use of an investigational drug or device (other than the study drug/device used in this study), or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study. [26] Have previously completed or withdrawn from this study after having signed the ICD. [27] Are unwilling or unable to comply with the use of a data collection device to directly record data from the patient.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
1. Day 6 of 6 days (6D) of pump reservoir in-use of Humalog is noninferior to Day 6 of 6D of pump reservoir in-use of insulin aspart with regards to 7-point daily mean SMBG (with margin of 06. mmol/L) 2. Day 6 of 6D of pump reservoir in-use of Humalog is superior to Day 6 of 6D of pump reservoir in-use of insulin aspart with regards to 7-point daily mean SMBG. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | Yes |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 6 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 4 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
It is defined in the protocol. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 12 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 12 |
E.8.9.2 | In all countries concerned by the trial days | 0 |